Photodynamic Therapy of Primary Localized Prostate Cancer With the SpectraCure P18 System

The goal of this study is to obtain safety data, establish dose parameters, and effectiveness of treatment for the SpectraCure P18 System with IDOSE®, together with verteporfin for injection (VFI) as photosensitizer, for the treatment of primary localized prostate cancer. The study will be divided into two parts, with Phase I, dose-escalation, to study safety and establish an effective light dose, followed by Phase II, cohort expansion, to evaluate clinical efficacy and confirm safety/tolerability. The subjects will be followed for a period of 18 months to determine the primary outcome. The l

Trial Details

NCT ID
NCT06807359
Phase
PHASE1 / PHASE2
Sponsor
SpectraCure AB
Status
RECRUITING
Cancer Type
Prostate Cancer
Interventions
  • Photodynamic Therapy (PDT)
  • Verteporfin Injection
Locations (sample)
  • New York, New York, United States|40.71427,-74.00597
  • Cologne, Germany|50.93333,6.95
  • Rostock, Germany|54.0887,12.14049

Key Eligibility Criteria

  • Subjects ≥ 18 years.
  • Histologically confirmed organ-confined adenocarcinoma of the prostate cancer diagnosed within the last 9 months. Including subjects on active surv…
  • a. This prostate biopsy should be targeted and systematic (transperineal or transrectal are both acceptable) and include both systematic sampling w…
  • Gleason Score 7 (3+4 or 4+3).

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Prostate Cancer Trials on Trialify →